These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 20190192)

  • 1. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.
    Markley JC; Sadelain M
    Blood; 2010 Apr; 115(17):3508-19. PubMed ID: 20190192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
    Pegram HJ; Purdon TJ; van Leeuwen DG; Curran KJ; Giralt SA; Barker JN; Brentjens RJ
    Leukemia; 2015 Feb; 29(2):415-22. PubMed ID: 25005243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric γc cytokine receptors confer cytokine independent engraftment of human T lymphocytes.
    Hunter MR; Prosser ME; Mahadev V; Wang X; Aguilar B; Brown CE; Forman SJ; Jensen MC
    Mol Immunol; 2013 Nov; 56(1-2):1-11. PubMed ID: 23628622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
    Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
    Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes.
    Kaneko S; Mastaglio S; Bondanza A; Ponzoni M; Sanvito F; Aldrighetti L; Radrizzani M; La Seta-Catamancio S; Provasi E; Mondino A; Nagasawa T; Fleischhauer K; Russo V; Traversari C; Ciceri F; Bordignon C; Bonini C
    Blood; 2009 Jan; 113(5):1006-15. PubMed ID: 18978209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
    Kinter AL; Godbout EJ; McNally JP; Sereti I; Roby GA; O'Shea MA; Fauci AS
    J Immunol; 2008 Nov; 181(10):6738-46. PubMed ID: 18981091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
    Xu Y; Zhang M; Ramos CA; Durett A; Liu E; Dakhova O; Liu H; Creighton CJ; Gee AP; Heslop HE; Rooney CM; Savoldo B; Dotti G
    Blood; 2014 Jun; 123(24):3750-9. PubMed ID: 24782509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.
    Simpson-Abelson MR; Sonnenberg GF; Takita H; Yokota SJ; Conway TF; Kelleher RJ; Shultz LD; Barcos M; Bankert RB
    J Immunol; 2008 May; 180(10):7009-18. PubMed ID: 18453623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
    Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
    Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
    Brentjens RJ; Latouche JB; Santos E; Marti F; Gong MC; Lyddane C; King PD; Larson S; Weiss M; Rivière I; Sadelain M
    Nat Med; 2003 Mar; 9(3):279-86. PubMed ID: 12579196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells.
    Marton C; Mercier-Letondal P; Galaine J; Godet Y
    Cell Immunol; 2021 May; 363():104314. PubMed ID: 33677140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis.
    Ma A; Koka R; Burkett P
    Annu Rev Immunol; 2006; 24():657-79. PubMed ID: 16551262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
    Dreier T; Baeuerle PA; Fichtner I; Grün M; Schlereth B; Lorenczewski G; Kufer P; Lutterbüse R; Riethmüller G; Gjorstrup P; Bargou RC
    J Immunol; 2003 Apr; 170(8):4397-402. PubMed ID: 12682277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
    Sabatino M; Hu J; Sommariva M; Gautam S; Fellowes V; Hocker JD; Dougherty S; Qin H; Klebanoff CA; Fry TJ; Gress RE; Kochenderfer JN; Stroncek DF; Ji Y; Gattinoni L
    Blood; 2016 Jul; 128(4):519-28. PubMed ID: 27226436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.